Exclusive Networks Appoints Jesper Trolle as CEO
15.9.2020 10:00:00 EEST | Business Wire | Press release
Exclusive Networks (‘Exclusive’) today announced the appointment of Jesper Trolle as CEO with immediate effect. Trolle joins Exclusive from ECS Arrow Electronics, where he is currently President of the Americas, and will be responsible for driving the next phase of growth at the company and upscaling the business. Trolle takes over from Olivier Breittmayer who becomes a non-executive Board member of Exclusive. The move is part of a planned succession strategy and Trolle will work alongside Breittmayer for the next three months to ensure a smooth transition.
Vastly experienced and recognised as an entrepreneurial business leader within the IT industry, Trolle has spent over 28 years working in the sector, initially within the reseller community, before moving into distribution. In 2001 he founded Next Denmark A/S which was acquired by DNS Denmark, which in turn was acquired by Arrow in 2005. Since then, Jesper has held a number of diverse positions in multiple locations within Arrow, seeing rapid success and progression, including stints in Germany running central and eastern Europe, and Paris, running north-west Europe. He took up the role as Arrow’s President Americas in 2017, based out of Denver, Colorado, where he has successfully grown a double-digit $bn business.
Speaking about the appointment, Breittmayer said, “Jesper was the standout choice following an intensive search and selection process these last six months or so. His cultural and international experience, obvious entrepreneurial DNA, knowledge of upscaling global businesses at pace and empathy with value-based distribution is impressive and refreshing. It is with confidence and a smile that we are getting such a capable person to take over the helm of the business we’ve grown by some 2,000% over the last 17 years.”
Talking of his appointment Trolle added, “Opportunities like this do not come around that often, but in distribution, Exclusive is at the top of the list if they do. I’m delighted to be joining such a successful company with a strong reputation for innovation and exceptional growth. Exclusive is renowned for its disruptive approach and relentless focus on value creation for its partners. When given the opportunity to become a part of the Exclusive family and next phase of its journey, it was an easy and fast decision to make.
“Olivier’s vision of creating the only specialist distributor on a global scale, focused on high performance cybersecurity infrastructure, was imaginative and disruptive – and that vision has become reality. Exclusive continues to buck market trends, growing at pace organically, expanding geographically and still disrupting. The only thing that hasn’t changed or been diluted is the obsession with value, services and specialism. This scale and specialist approach has never before been achieved. My job is clear: turn the global presence into a cybersecurity infrastructure powerhouse, at scale and speed, and it is a challenge I relish, feel qualified to do and very much look forward to,” concluded Trolle.
Michail Zekkos, Partner at Permira, and a member of Exclusive’s Board of Directors, commented, “Olivier is a pioneer and a true inspiration in modern day value-based distribution. It was a hard task to find his natural replacement, but in Jesper we feel we have done just that. He’s exceptionally talented and culturally very aligned to L’Esprit Exclusive. Olivier’s vision of building the Exclusive ‘Network’ of value-based distribution businesses, globally guided but locally delivered, was unique.
“The business has consistently outperformed market growth rates; expanded at breathtaking speed and delivered financial results that are exceptional for the sector. This is a great platform from which Jesper can continue the adventure and scale-out the business, and with his vision, multicultural background and experience of growth at scale we feel confident he is more than able to meet the challenge.
“Myself and the rest of the Exclusive family thank Olivier wholeheartedly for his indelible impact on the company, and welcome him onto the Board of Directors.”
Breittmayer added finally, “It’s not goodbye, it’s à plus tard.”
-ends-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005084/en/
Contact information
Exclusive Networks Contact:
Jon Bawden
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
